Table I.
Properties of studies of MDD.
| Drug class | Drug formulation | Number of patients | Age range | Exclude at risk |
|---|---|---|---|---|
| SSRI | Citalopram (Celexa) | 178 | 7–17 | Yes |
| SSRI | Citalopram (Celexa) | 244 | 13–18 | No |
| SSRI | Paroxetine (Paxil) | 206 | 7–17 | Yes |
| SSRI | Paroxetine (Paxil) | 275 | 13–18 | Yes |
| SSRI | Paroxetine (Paxil) | 181 | 12–18 | Yes |
| SSRI | Fluoxetine (Prozac) | 221 | 12–17 | Yes |
| SSRI | Fluoxetine (Prozac) | 96 | 8–18 | No |
| SSRI | Fluoxetine (Prozac) | 219 | 8–17 | Yes |
| SSRI | Fluoxetine (Prozac) | 40 | 12–17 | Yes |
| SSRI | Sertraline (Zoloft) | 188 | 6–17 | Yes |
| SSRI | Sertraline (Zoloft) | 185 | 6–17 | Yes |
| Atypical | Venlafaxine (Effexor) | 165 | 7–17 | Yes |
| Atypical | Venlafaxine (Effexor) | 196 | 7–17 | Yes |
| Atypical | Mirtazapine (Remeron) | 259 | 7–17 | Yes |
| Atypical | Nefazodone (Serzone) | 278 | 7–17 | Yes |
| Atypical | Nefazodone (Serzone) | 190 | 12–17 | Yes |
Studies compared with YRBS estimates are in bold. SSRI denotes selective serotonin reuptake inhibitor.